BioAlliance Pharma submits NDA for fungal disease treatment

WOODCLIFF LAKE, N.J. The proprietary products division of generic drug maker Par Pharmaceuticals has announced that its development partner has submitted an application to the Food and Drug Administration for a branded drug to treat the fungal disease oropharyngeal candidiasis.

Strativa Pharmaceuticals said Tuesday that BioAlliance Pharma had submitted the application for Loramyc (miconazole Lauriad) mucoadhesive buccal tablets in the 50 mg strength, and that the tablets could be launched in the second half of 2010 if approved.

The drug was approved in the European Union in 2007 and is marketed in several EU countries, Strativa said.